Payment overview · 2025
General Payments
$517.19
24 reported records · 15 companies
Healthcare provider profile · identity verified
Michele M Cooper, MD
Allopathic & Osteopathic Physicians|Internal Medicine · NEW ORLEANS, LA · NPI 1700042256
Verified facts
What the public records show
CMS Open Payments records show Michele M Cooper, MD received $517.19 in general payments during 2025 across 24 reported records.
AstraZeneca Pharmaceuticals LP accounted for 36.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Linzess, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 181 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $188.14 | 36.4% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $51.05 | 9.9% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $46.84 | 9.1% | 3 | 2025 |
| Evofem Biosciences, Inc. | Unresolved — no canonical attribution shown | $29.71 | 5.7% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $28.65 | 5.5% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $23.55 | 4.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.98 | 3.9% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $18.89 | 3.6% | 1 | 2025 |
| Sage Therapeutics, LLC | Unresolved — no canonical attribution shown | $18.09 | 3.5% | 1 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.09 | 3.5% | 1 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $16.67 | 3.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.40 | 3.2% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.53 | 3.0% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $14.58 | 2.8% | 1 | 2025 |
| MAYNE PHARMA COMMERCIAL LLC | Unresolved — no canonical attribution shown | $11.02 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $517.19 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $115.48 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $65.21 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $64.17 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $32.68 | 2 | 2025 |
Source payment records
|
|||||
| Phexx Normalized: phexx |
Drug | Evofem Biosciences, Inc. | $29.71 | 2 | 2025 |
Source payment records
|
|||||
| Phexxi Normalized: phexxi |
Drug | Evofem Biosciences, Inc. | $29.71 | 2 | 2025 |
Source payment records
|
|||||
| Solosec Normalized: solosec |
Drug | Evofem Biosciences, Inc. | $29.71 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $28.65 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $23.55 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $19.98 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $19.98 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $18.89 | 1 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $18.09 | 1 | 2025 |
Source payment records
|
|||||
| ZURZUVAE Normalized: zurzuvae |
Drug | Sage Therapeutics, LLC | $18.09 | 1 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $16.67 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.59 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.40 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.53 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $14.58 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $8.49 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 65 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 81 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 81 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
81 | 21 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
65 | 20 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
65 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
81 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
120 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
181 | 34 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 902 | 261 |
| Atorvastatin Calcium | Atorvastatin Calcium | 670 | 193 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 438 | 137 |
| Losartan Potassium | Losartan Potassium | 424 | 112 |
| Hydrochlorothiazide | Hydrochlorothiazide | 331 | 98 |
| Metformin Hcl | Metformin Hcl | 306 | 87 |
| Metoprolol Succinate | Metoprolol Succinate | 283 | 80 |
| Gabapentin | Gabapentin | 281 | 84 |
| Lisinopril | Lisinopril | 268 | 82 |
| Zolpidem Tartrate | Zolpidem Tartrate | 252 | 41 |
| Metformin Hcl Er | Metformin Hcl | 247 | 76 |
| Omeprazole | Omeprazole | 215 | 60 |
| Alprazolam | Alprazolam | 198 | 37 |
| Ozempic | Semaglutide | 181 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 174 | 51 |
| Pravastatin Sodium | Pravastatin Sodium | 166 | 48 |
| Carvedilol | Carvedilol | 161 | 52 |
| Furosemide | Furosemide | 156 | 49 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 155 | 41 |
| Potassium Chloride | Potassium Chloride | 151 | 47 |
| Levothyroxine Sodium | Levothyroxine Sodium | 147 | 50 |
| Fluticasone Propionate | Fluticasone Propionate | 145 | 54 |
| Ibuprofen | Ibuprofen | 142 | 48 |
| Pantoprazole Sodium | Pantoprazole Sodium | 139 | 41 |
| Trulicity | Dulaglutide | 120 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 107 | 39 |
| Nifedipine Er | Nifedipine | 106 | 31 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 104 | 39 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 103 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 100 | 30 |
| Glimepiride | Glimepiride | 99 | 29 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 96 | 39 |
| Simvastatin | Simvastatin | 93 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 88 | 31 |
| Diazepam | Diazepam | 86 | 23 |
| Tramadol Hcl | Tramadol Hcl | 86 | 48 |
| Allopurinol | Allopurinol | 85 | 27 |
| Montelukast Sodium | Montelukast Sodium | 82 | 22 |
| Linzess | Linaclotide | 81 | 21 |
| Mounjaro | Tirzepatide | 81 | 15 |
| Famotidine | Famotidine | 80 | 28 |
| Alendronate Sodium | Alendronate Sodium | 76 | 25 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 75 | 24 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 72 | 23 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 72 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 71 | 23 |
| Meloxicam | Meloxicam | 70 | 27 |
| Clonidine Hcl | Clonidine Hcl | 68 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 68 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 67 | 20 |
| Jardiance | Empagliflozin | 65 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 65 | 21 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 64 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 63 | 18 |
| Glipizide | Glipizide | 62 | 17 |
| Meclizine Hcl | Meclizine Hcl | 62 | 19 |
| Fluconazole | Fluconazole | 61 | 29 |
| Temazepam | Temazepam | 61 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 59 | 22 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 56 | 24 |
| Eliquis | Apixaban | 53 | 12 |
| Trazodone Hcl | Trazodone Hcl | 53 | 17 |
| Methylprednisolone | Methylprednisolone | 52 | 41 |
| Lorazepam | Lorazepam | 51 | 14 |
| Benazepril Hcl | Benazepril Hcl | 50 | 15 |
| Azithromycin | Azithromycin | 46 | 38 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 46 | 38 |
| Sertraline Hcl | Sertraline Hcl | 46 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 43 | 14 |
| Irbesartan | Irbesartan | 42 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 39 | 11 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 39 | 13 |
| Valsartan | Valsartan | 39 | 13 |
| Donepezil Hcl | Donepezil Hcl | 38 | 16 |
| Ondansetron Odt | Ondansetron | 37 | 17 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 36 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 36 | suppressed |
| Celecoxib | Celecoxib | 35 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 35 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 34 | suppressed |
| Atenolol | Atenolol | 32 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 32 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 32 | 20 |
| Januvia | Sitagliptin Phosphate | 32 | suppressed |
| Mupirocin | Mupirocin | 32 | 14 |
| Spironolactone | Spironolactone | 32 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 32 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 30 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 29 | 22 |
| Nebivolol Hcl | Nebivolol Hcl | 29 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | suppressed |
| Clonazepam | Clonazepam | 28 | suppressed |
| Naproxen | Naproxen | 28 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 26 | suppressed |
| Mirtazapine | Mirtazapine | 25 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 25 | suppressed |
| Lovastatin | Lovastatin | 24 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 24 | suppressed |
| Ketoconazole | Ketoconazole | 23 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 23 | suppressed |
| Amoxicillin | Amoxicillin | 22 | 11 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 22 | suppressed |
| Latanoprost | Latanoprost | 22 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 15 |
| Pregabalin | Pregabalin | 21 | suppressed |
| Baclofen | Baclofen | 20 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 20 | suppressed |
| Tradjenta | Linagliptin | 20 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 19 | suppressed |
| Colchicine | Colchicine | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 13 |
| Azelastine Hcl | Azelastine Hcl | 18 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 18 | suppressed |
| Indapamide | Indapamide | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Fluocinonide | Fluocinonide | 16 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 16 | suppressed |
| Lactulose | Lactulose | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 14 | suppressed |
| Indomethacin | Indomethacin | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Prednisone | Prednisone | 14 | suppressed |
| Budesonide Er | Budesonide | 13 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 11 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Ezetimibe | Ezetimibe | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Ibu | Ibuprofen | 12 | suppressed |
| Terconazole | Terconazole | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $517.19 · 24 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, BREZTRI, Cologuard Collection Kit, FARXIGA, Heplisav-B, INSPIRE, JARDIANCE, Korlym, LINZESS, MOUNJARO, Phexx, Phexxi, Qelbree, SHINGRIX, Solosec, Wegovy, ZEPBOUND, ZORYVE, ZURZUVAE | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error